Venetoclax Combined With FLAG ‐ IDA in Refractory or Relapsed Acute Myeloid Leukemia
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14302 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Kai Wille und 12 weiteren Autor:innen. Beteiligte Einrichtung: University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden,…. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides, Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The prognosis of patients with refractory or relapsed AML (R/R‐AML) is very limited. To (re)achieve complete remission, there has recently been increasing evidence that the combination of venetoclax (VEN) with chemotherapy is associated with improved outcomes. Patients and Methods Our retrospective, single‐center study of 53 R/R‐AML patients with a median follow‐up time of 11.0 months compared standard salvage chemotherapy (FLAG‐Ida or HAM in n = 35 patients) with a combination of venetoclax (VEN) and FLAG‐Ida (FLAVIDA in n = 18 patients) concerning safety and efficacy.
Results
Regarding the primary endpoints, there was a statistically significant increased event free survival (EFS) in the FLAVIDA group compared to patients with standard chemotherapy based on the univariate log‐rank‐test and in the multivariate Cox regression analysis (HR 0.22 [95% CI 0.05, 0.97]). There were no differences between the two groups in terms of patients developing febrile neutropenia CTCAE III° and IV° or a delay in hematological recovery. In addition, a clear trend towards an improved overall response rate (78% vs. 51%) was demonstrated in the FLAVIDA group.
Conclusions
The FLAVIDA regimen represents a promising treatment alternative for R/R AML patients with a high response rate and significantly improved EFS compared to standard chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany.
- Core Facility Statistical Consulting, Helmholtz Zentrum München, Munich, Germany.
- Faculty of Business Administration and Economics, Bielefeld University, Bielefeld, Germany.
ORCID-Profile: Kai Wille
Zitieren
APA
Wille, K., Dumke, M., Wilsdorf, N., Sadjadian, P., Schneider, A., Jender-Bartling, S., Kolatzki, V., Horstmann, A., Meixner, R., Jiménez-Muñoz, M., Fuchs, C., Tischler, H. J., & Griesshammer, M. (2025). Venetoclax Combined With FLAG ‐ IDA in Refractory or Relapsed Acute Myeloid Leukemia. European Journal of Haematology. https://doi.org/10.1111/ejh.14302
Vancouver
Wille K, Dumke M, Wilsdorf N, Sadjadian P, Schneider A, Jender-Bartling S, et al. Venetoclax Combined With FLAG ‐ IDA in Refractory or Relapsed Acute Myeloid Leukemia. European Journal of Haematology. 2025. doi:10.1111/ejh.14302
BibTeX
@article{Wille2025,
author = {Wille, Kai and Dumke, Marvin and Wilsdorf, Nadine and Sadjadian, Parvis and Schneider, Artur and Jender-Bartling, Stephanie and Kolatzki, Vera and Horstmann, Anette and Meixner, Raphael and Jiménez-Muñoz, Marina and Fuchs, Christiane and Tischler, Hans-Joachim and Griesshammer, Martin},
title = {Venetoclax Combined With FLAG ‐ IDA in Refractory or Relapsed Acute Myeloid Leukemia},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14302}
}
EUVIMED